{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:48:59Z","timestamp":1782935339323,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.meegid.2020.104186","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:42:04Z","timestamp":1578444124000},"page":"104186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Epitope promiscuity and population coverage of Mycobacterium tuberculosis protein antigens in current subunit vaccines under development"],"prefix":"10.1016","volume":"80","author":[{"given":"Edison","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-9661","authenticated-orcid":false,"given":"Yongqun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2020.104186_bb0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm.2285","article-title":"A multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","author":"Aagaard","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.meegid.2020.104186_bb0010","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.4049\/jimmunol.181.11.7948","article-title":"Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis","volume":"181","author":"Bertholet","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.meegid.2020.104186_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1745-7580-3-10","article-title":"An analysis of the epitope knowledge related to mycobacteria","volume":"3","author":"Blythe","year":"2007","journal-title":"Immunome Res."},{"key":"10.1016\/j.meegid.2020.104186_bb0020","series-title":"Handbook of Global Tuberculosis Control: Practices and Challenges","first-page":"437","article-title":"The promise of new TB vaccines","author":"Brennan","year":"2017"},{"key":"10.1016\/j.meegid.2020.104186_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting population coverage of T-cell epitope-based diagnostics and vaccines","volume":"7","author":"Bui","year":"2006","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.meegid.2020.104186_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003266","article-title":"Properties of MHC class I presented peptides that enhance immunogenicity","volume":"9","author":"Calis","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.meegid.2020.104186_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2019.1585246","article-title":"Deciphering protective immunity against tuberculosis: implications for vaccine development","volume":"18","author":"Counoupas","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.meegid.2020.104186_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/annotation\/ff089043-990a-48c2-a90f-15606c11cc98","article-title":"Comparison of the predicted population coverage of tuberculosis vaccine candidates Ag85b-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach","volume":"7","author":"Davila","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.meegid.2020.104186_bb0045","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"Fine","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2020.104186_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.00278","article-title":"The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design","volume":"8","author":"Fleri","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.meegid.2020.104186_bb0055","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.meegid.2020.104186_bb0060","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonz\u00e1lez-Galarza","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.meegid.2020.104186_bb0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00251-011-0513-0","article-title":"Functinal classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes","volume":"63","author":"Greenbaum","year":"2013","journal-title":"Immunogenetics"},{"key":"10.1016\/j.meegid.2020.104186_bb0070","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/IAI.00335-07","article-title":"DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy","volume":"75","author":"Hebert","year":"2007","journal-title":"Infect. Immun."},{"key":"10.1016\/j.meegid.2020.104186_bb0075","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.4049\/jimmunol.0901607","article-title":"Quantitating T cell cross-reactivity for unrelated peptide antigens","volume":"183","author":"Ishizuka","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.meegid.2020.104186_bb0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coi.2017.07.008","article-title":"Tuberculosis vaccines \u2014 perspectives from the NIH\/NIAID mycobacteria vaccine testing program","volume":"47","author":"Izzo","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.meegid.2020.104186_bb0085","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.4049\/jimmunol.181.3.2124","article-title":"Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance","volume":"181","author":"Kotturi","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.meegid.2020.104186_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005760","article-title":"A quantitative analysis of complexity of human pathogen-specific CD4 T cell responses in healthy M. tuberculosis infected South Africans","volume":"12","author":"Lindestam Arlehamn","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.meegid.2020.104186_bb0095","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.meegid.2020.104186_bb0100","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00251-004-0647-4","article-title":"Definition of supertypes for HLA molecules using clustering of specificity matrices","volume":"55","author":"Lund","year":"2004","journal-title":"Immunogenetics"},{"key":"10.1016\/j.meegid.2020.104186_bb0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2172-11-18","article-title":"Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis","volume":"11","author":"McNamara","year":"2010","journal-title":"BMC Immunol."},{"key":"10.1016\/j.meegid.2020.104186_bb0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nbt1215","article-title":"A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus","volume":"24","author":"Moutaftsi","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.meegid.2020.104186_bb0115","first-page":"2773","article-title":"Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6","volume":"69","author":"Olsen","year":"2001","journal-title":"Microbiology"},{"key":"10.1016\/j.meegid.2020.104186_bb0120","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93+GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.meegid.2020.104186_bb0125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.meegid.2017.09.023","article-title":"Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa","volume":"55","author":"Perez-Martinez","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.meegid.2020.104186_bb0130","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1128\/JVI.02632-06","article-title":"The CD8+ T-cell response to lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an old virus","volume":"81","author":"Peters","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2020.104186_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006250","article-title":"Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine","volume":"13","author":"Prados-Rosales","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.meegid.2020.104186_bb0140","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.meegid.2020.104186_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1007643","article-title":"A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates","volume":"15","author":"Rodo","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.meegid.2020.104186_bb0150","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.12688\/f1000research.16521.2","article-title":"Research and development of new tuberculosis vaccines: a review","volume":"7","author":"Schrager","year":"2019","journal-title":"F1000Res."},{"issue":"1","key":"10.1016\/j.meegid.2020.104186_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2172-9-1","article-title":"HLA class I supertypes: a revised and updated classification","volume":"9","author":"Sidney","year":"2008","journal-title":"BMC Immunol."},{"key":"10.1016\/j.meegid.2020.104186_bb0160","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1128\/IAI.67.8.3998-4007.1999","article-title":"Evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis","volume":"67","author":"Skeiky","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.meegid.2020.104186_bb0165","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/9858","article-title":"Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices","volume":"17","author":"Sturniolo","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.meegid.2020.104186_bb0170","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/rccm.201802-0366OC","article-title":"Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations a double-blind, placebo-controlled, dose-selection trial","volume":"199","author":"Suliman","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.meegid.2020.104186_bb0175","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO\u2019s new end TB strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.meegid.2020.104186_bb0180","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4","article-title":"Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells","volume":"30","author":"Van Pinxteren","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.meegid.2020.104186_bb0185","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.meegid.2020.104186_bb0190","series-title":"Global Tuberculosis Report 2017: MDR\/RR-TB Update","author":"World Health Organization","year":"2017"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134820300186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134820300186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:42:22Z","timestamp":1761576142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134820300186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":38,"alternative-id":["S1567134820300186"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2020.104186","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epitope promiscuity and population coverage of Mycobacterium tuberculosis protein antigens in current subunit vaccines under development","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2020.104186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104186"}}